GATA

A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas

Open at Saint-Cloud since : 21/09/2018
Target : Adult
Phase : Phase II

Trial description

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts:;Àrelapsed/refractory follicular lymphoma (FL) patients;Àrelapsed/refractory aggressive (DLBCL) lymphoma patients;Àrelapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)

Url of the trial

Main investigator

CAROLE SOUSSAIN

Médecin

Contact